{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Paralysie pseudobulbaire : Questions médicales les plus fréquentes",
"headline": "Paralysie pseudobulbaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Paralysie pseudobulbaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-02",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Paralysie pseudobulbaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Paralysie",
"url": "https://questionsmedicales.fr/mesh/D010243",
"about": {
"@type": "MedicalCondition",
"name": "Paralysie",
"code": {
"@type": "MedicalCode",
"code": "D010243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.636"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Paralysie pseudobulbaire",
"alternateName": "Pseudobulbar Palsy",
"code": {
"@type": "MedicalCode",
"code": "D020828",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kenjiro Kunieda",
"url": "https://questionsmedicales.fr/author/Kenjiro%20Kunieda",
"affiliation": {
"@type": "Organization",
"name": "Neurology, Gifu University Graduate School of Medicine, Gifu, JPN."
}
},
{
"@type": "Person",
"name": "Tomohisa Ohno",
"url": "https://questionsmedicales.fr/author/Tomohisa%20Ohno",
"affiliation": {
"@type": "Organization",
"name": "Dentistry, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN."
}
},
{
"@type": "Person",
"name": "Ichiro Fujishima",
"url": "https://questionsmedicales.fr/author/Ichiro%20Fujishima",
"affiliation": {
"@type": "Organization",
"name": "Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN."
}
},
{
"@type": "Person",
"name": "Victor Kekere",
"url": "https://questionsmedicales.fr/author/Victor%20Kekere",
"affiliation": {
"@type": "Organization",
"name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA."
}
},
{
"@type": "Person",
"name": "Patrice Fouron",
"url": "https://questionsmedicales.fr/author/Patrice%20Fouron",
"affiliation": {
"@type": "Organization",
"name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism.",
"datePublished": "2023-10-03",
"url": "https://questionsmedicales.fr/article/37834323",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241914874"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms.",
"datePublished": "2023-03-09",
"url": "https://questionsmedicales.fr/article/36980189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells12060848"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.",
"datePublished": "2022-05-22",
"url": "https://questionsmedicales.fr/article/35560866",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/dta.3283"
}
},
{
"@type": "ScholarlyArticle",
"name": "Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.",
"datePublished": "2023-02-21",
"url": "https://questionsmedicales.fr/article/36708234",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/febs.16741"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.",
"datePublished": "2024-10-18",
"url": "https://questionsmedicales.fr/article/38936978",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1124/jpet.124.002129"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Paralysie",
"item": "https://questionsmedicales.fr/mesh/D010243"
},
{
"@type": "ListItem",
"position": 6,
"name": "Paralysie pseudobulbaire",
"item": "https://questionsmedicales.fr/mesh/D020828"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Paralysie pseudobulbaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Paralysie pseudobulbaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Paralysie pseudobulbaire",
"description": "Comment diagnostique-t-on la paralysie pseudobulbaire ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes aident au diagnostic ?\nLa paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?\nPeut-on confondre cette paralysie avec d'autres troubles ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoid+Receptor+Agonists#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Paralysie pseudobulbaire",
"description": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?\nLa difficulté à parler est-elle un symptôme courant ?\nLes patients ressentent-ils de la douleur ?\nY a-t-il des variations dans les symptômes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoid+Receptor+Agonists#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Paralysie pseudobulbaire",
"description": "Peut-on prévenir la paralysie pseudobulbaire ?\nComment réduire le risque de paralysie pseudobulbaire ?\nLes AVC peuvent-ils être prévenus ?\nLa réhabilitation précoce aide-t-elle à prévenir la paralysie ?\nLes habitudes alimentaires influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoid+Receptor+Agonists#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Paralysie pseudobulbaire",
"description": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?\nLa rééducation est-elle utile ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces pour tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoid+Receptor+Agonists#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Paralysie pseudobulbaire",
"description": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?\nLa dépression est-elle une complication fréquente ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques d'isolement social ?\nLes complications peuvent-elles être traitées ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoid+Receptor+Agonists#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Paralysie pseudobulbaire",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de paralysie pseudobulbaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie peut-il influencer le risque ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoid+Receptor+Agonists#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la paralysie pseudobulbaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie cérébrale comme l'IRM peuvent être utilisés pour identifier les lésions."
}
},
{
"@type": "Question",
"name": "Quels symptômes aident au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des accès de rire ou de pleurs inappropriés et des troubles de la parole."
}
},
{
"@type": "Question",
"name": "La paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent associée à des maladies neurologiques comme la sclérose en plaques ou les AVC."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette paralysie avec d'autres troubles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres troubles affectant le contrôle émotionnel et moteur."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux symptômes incluent des crises de rire ou de pleurs incontrôlables."
}
},
{
"@type": "Question",
"name": "La difficulté à parler est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent éprouver des difficultés à articuler et à contrôler leur voix."
}
},
{
"@type": "Question",
"name": "Les patients ressentent-ils de la douleur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La paralysie pseudobulbaire ne cause généralement pas de douleur physique, mais des malaises émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des variations dans les symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en intensité et en fréquence d'un patient à l'autre."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent s'aggraver et affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la paralysie pseudobulbaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais la gestion des maladies sous-jacentes peut aider."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de paralysie pseudobulbaire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et traiter les affections neurologiques peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les AVC peuvent-ils être prévenus ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en contrôlant les facteurs de risque comme l'hypertension et le diabète, on peut réduire les AVC."
}
},
{
"@type": "Question",
"name": "La réhabilitation précoce aide-t-elle à prévenir la paralysie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une réhabilitation précoce après un AVC ou une lésion cérébrale peut aider à prévenir la paralysie."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut contribuer à la santé neurologique et réduire les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments comme les antidépresseurs et la thérapie comportementale."
}
},
{
"@type": "Question",
"name": "La rééducation est-elle utile ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation orthophonique peut aider à améliorer les capacités de communication."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils réduire les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent réduire la fréquence et l'intensité des épisodes émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la thérapie psychologique peuvent également être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour tous les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements peut varier selon les individus et la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles de la déglutition et des problèmes de communication."
}
},
{
"@type": "Question",
"name": "La dépression est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent développer une dépression en raison de l'impact émotionnel de la maladie."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'isolement social ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les difficultés de communication peuvent entraîner un isolement social pour les patients."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées avec des traitements appropriés et un soutien."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les AVC, les maladies neurodégénératives et les traumatismes crâniens sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de paralysie pseudobulbaire ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées ayant des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies cardiovasculaires augmentent le risque de paralysie pseudobulbaire par AVC."
}
}
]
}
]
}
From the Departments of Pediatrics and Neurology/Neurosurgery, McGill University; and Division of Pediatric Neurology, Montreal Children's Hospital-McGill University Health Centre, Canada. michael.shevell@muhc.mcgill.ca.
Division of Occupational Therapy and Physical Therapy, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 4007, Cincinnati, OH 45229, USA.
Faculty of Medicine (JPL), McGill University, Montreal, QC; Department of Pediatrics and Neurology and Neurosurgery (MO, MS), McGill University, Montreal, QC; Centre for Outcomes Research and Evaluation (MO, PN, MS), Research Institute of the McGill University Health Centre, Montreal, QC; Department of Pediatrics (JA), University of Alberta, Edmonton, AB; Janeway Children's Hospital (DB), St. John's, NL; Department of Paediatrics (DF), University of Toronto, Bloorview Research Institute, Toronto, ON; Departments of Pediatrics and Clinical Neurosciences (AK), Cumming School of Medicine, University of Calgary, AB; Centre de réadaptation Marie Enfant du CHU Sainte-Justine (LK), Montreal, QC; Centre hospitalier universitaire de Sherbrooke (NP), Sherbrooke, QC; BC Children's Hospital (EvR), Vancouver, BC; and IWK Health Centre (EW), Halifax, NS, Canada.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Synthetic cannabinoid receptor agonists (SCRAs) have become a wide group of new psychoactive substances since the 2010s. For the last few years, the X-ray structures of the complexes of cannabinoid re...
Cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2) are components in the endocannabinoid system that play significant roles in regulating immune responses. There are many agonists for the c...
In recent years, several nations have implemented various measures to control the surge of new synthetic cannabinoid receptor agonists (SCRAs) entering the recreational drug market. In July 2021, Chin...
Synthetic cannabinoid receptor agonists (SCRAs) are one of the fastest growing classes of recreational drugs. Despite their growth in use, their vast chemical diversity and rapidly changing landscape ...
Endocannabinoids, which are present throughout the central nervous system (CNS), can activate cannabinoid receptors 1 and 2 (CB1 and CB2). CB1 and CB2 agonists exhibit broad anti-inflammatory properti...
Since late 2019, fortification of 'regular' cannabis plant material with synthetic cannabinoid receptor agonists (SCRAs) has become a notable phenomenon on the drug market. As many SCRAs pose a higher...
The assay principle relies on the functional complementation of a split-nanoluciferase following recruitment of β-arrestin 2 to activated CB...
The bioassay successfully detected all samples of a set (n = 24) of analytically confirmed authentic Spice products, additionally providing relevant information on the 'strength' of a preparation and ...
In summary, we established SCRA screening of herbal materials as a new application for the activity-based CB...
Partial agonists of peripheral cannabinoid receptors (CBRs) have potential therapeutic applications in several medical conditions. However, (-)-trans-Δ...
Cannabinoid receptor ligands are renowned as being therapeutically crucial for treating diverse health disorders. Phenylspirodrimanes are meroterpenoids with unique and varied structural scaffolds, wh...
The emergence of synthetic cannabinoid receptor agonists (SCRAs) as illicit psychoactive substances has posed considerable public health risks, including fatalities. Many SCRAs exhibit much higher eff...
Following the class-wide ban of synthetic cannabinoid receptor agonists (SCRAs) in China, SCRAs carrying new core and linker structures, aimed at circumventing the recent Chinese generic legislation, ...